Kamada (NASDAQ:KMDA) Issues Quarterly Earnings Results

Kamada (NASDAQ:KMDA) released its quarterly earnings data on Monday. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01, FiscalAI reports. The business had revenue of $52.03 million for the quarter, compared to the consensus estimate of $52.51 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%.

Kamada Stock Performance

Shares of NASDAQ KMDA opened at $7.23 on Monday. Kamada has a 12 month low of $6.55 and a 12 month high of $9.35. The firm has a market capitalization of $415.80 million, a PE ratio of 19.03, a price-to-earnings-growth ratio of 0.61 and a beta of 0.90. The firm has a fifty day simple moving average of $8.08 and a two-hundred day simple moving average of $8.00.

Kamada Cuts Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were issued a $0.17 dividend. This is a drop from Kamada’s previous annual dividend of $0.25. The ex-dividend date was Thursday, August 27th. This represents a yield of 206.0%. Kamada’s dividend payout ratio (DPR) is currently 34.21%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on KMDA. William Blair set a $15.00 price target on shares of Kamada in a research report on Tuesday, July 21st. UBS Group restated a “buy” rating and set a $15.00 price target on shares of Kamada in a report on Friday, September 18th. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Weiss Ratings raised Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. Finally, Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, Kamada has an average rating of “Buy” and an average price target of $13.50.

About Kamada

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.